Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03212404 |
|
Recruitment Status :
Recruiting
First Posted : July 11, 2017
Last Update Posted : August 29, 2023
|
Sponsor:
Checkpoint Therapeutics, Inc.
Collaborator:
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Checkpoint Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Actual Primary Completion Date : | November 18, 2021 |
| Estimated Study Completion Date : | December 2024 |